Role of the AT2 receptor in modulating the angiotensin II contractile response of the uterine artery at mid-gestation by Pulgar, V. M. et al.
Campbell University 
CU FIND 
Pharmaceutical Sciences Pharmacy & Health Sciences, College of 
3-18-2011 
Role of the AT2 receptor in modulating the angiotensin II 
contractile response of the uterine artery at mid-gestation 
V. M. Pulgar 
H. Yamashiro 
J. C. Rose 
L. G. Moore 
Follow this and additional works at: https://cufind.campbell.edu/pharmacy 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
Recommended Citation 
Pulgar, V. M.; Yamashiro, H.; Rose, J. C.; and Moore, L. G., "Role of the AT2 receptor in modulating the 
angiotensin II contractile response of the uterine artery at mid-gestation" (2011). Pharmaceutical 
Sciences. 2192. 
https://cufind.campbell.edu/pharmacy/2192 
This Article is brought to you for free and open access by the Pharmacy & Health Sciences, College of at CU FIND. It 
has been accepted for inclusion in Pharmaceutical Sciences by an authorized administrator of CU FIND. For more 
information, please contact long@campbell.edu. 
1 Department of Obstetrics and Gynecology, Wake Forest University, 
Winston-Salem, NC, USA
2 Center for Research in Obstetrics and Gynecology, Wake Forest 
University, Winston-Salem, NC, USA 
3 Department of Physiology and Pharmacology, Wake Forest University, 
Winston-Salem, NC, USA
4 Graduate School of Arts and Sciences, Wake Forest University, 
Winston-Salem, NC, USA
Corresponding author:
Victor M Pulgar, Department of Obstetrics and Gynecology, Wake 
Forest University School of Medicine, Winston-Salem NC 27157, USA. 
Email: vpulgar@wfubmc.edu
Journal of the Renin-Angiotensin-
Aldosterone System
12(3) 176 –183
© The Author(s) 2011
Reprints and permission:  
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/1470320310397406 
jra.sagepub.com
Article
Role of the AT2 receptor in modulating  
the angiotensin II contractile response  
of the uterine artery at mid-gestation
Victor M Pulgar1,2, Henry Yamashiro1, James C Rose1,2,3  
and Lorna G Moore1,4
Abstract
Introduction: During human pregnancy, circulating concentrations of components of the renin–angiotensin system 
increase, but pressor refractoriness to angiotensin II (Ang-II) is observed. Given the importance of the Ang-II pressor 
response in deciding susceptibility to preeclampsia and of the Ang-II system for controlling uterine vasoreactivity, we 
sought to address the effects of pregnancy on the reactivity of the isolated uterine artery (UA) in mice. 
Materials and methods: Blood pressure was measured throughout pregnancy in awake C57BL/6J mice. UA segments were 
isolated from three groups of animals (non-pregnant, mid [day 12–13] and late [day 18–19] gestation) and studied by 
wire myography.
Results: UA diameters, KCl-mediated responses, and acetylcholine-dependent vasorelaxation were greater at mid and 
late gestation than in non-pregnant animals. Ang-II responses were also greater during pregnancy, with an increased 
contraction in response to AT2 receptor blockade at mid-gestation. AT1 receptor blockade abolished the Ang-II 
response in all groups. 
Conclusions: Study findings are consistent with the possibility that AT2 receptor-mediated vasodilatation plays a role in 
modulating Ang-II contractile responses in pregnancy.
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Introduction
The uterine artery (UA) and uterine circulation in general 
make major contributions to the decline in systemic vascular 
resistance during pregnancy.1 In human pregnancy at term, 
total uteroplacental flow increases approximately 50-fold, 
representing nearly 20% of the cardiac output (CO).2-4 As 
part of the maternal cardiovascular responses to pregnancy, 
the UA undergoes pronounced vasodilatation, growth and 
remodelling in all species studied to date. Integral to these 
changes are the UA’s increased vasodilator response to flow 
and pharmacological agonists, greater DNA production, 
increased proliferative response of UA vascular smooth 
muscle cells, increased force-generating capacity of the UA 
smooth muscle, outward hypertrophic remodelling and con-
sequent enlargement in luminal diameter.2,5-8
The renin–angiotensin system (RAS) affects both 
vasoactive and vascular growth and remodelling-related 
processes in the systemic as well as the uteroplacental cir-
culations. One of its most important components is the 
octapeptide angiotensin II (Ang-II), whose actions are 
mediated by type 1 (AT1) and type 2 (AT2) membrane 
receptors. The use of non-peptide blockers9 has shown that 
most of Ang-II’s vasoconstrictor effects are mediated by the 
AT1 receptor,10 whereas the AT2 receptor has been shown 
in several animal models and human studies to oppose 
AT1’s effects by causing vasodilatation and natriuresis.11-13
Several observations point to an important role for the 
RAS during pregnancy in both the systemic and uteropla-
cental circulations. In humans, plasma levels of Ang-II and 
other components of the RAS are increased; however, the 
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systemic pressor response to Ang-II is reduced.14,15 The 
absence of a blunted pressor response to Ang-II is among 
the few predictors of susceptibility for preeclampsia,15,16 
underscoring the importance of the RAS in this still poorly 
understood disease. In sheep, Ang-II vasoconstricts the 
uterine circulation, but the uterine compared with the sys-
temic vascular bed is relatively refractory to Ang-II. One 
reason for this may be that pregnancy increases UA AT2 
receptor density17 above its already elevated levels in the 
uterine circulation, where it comprises the majority of total 
Ang-II receptors.18,19 In addition to opposing AT1-mediated 
vasoconstriction, AT2 receptor activation also stimulates 
nitric oxide (NO) production.20 Increased production of NO 
and other endothelial substances, such as prostacyclin or 
endothelium-derived hyperpolarising factor, plays impor-
tant roles in increasing the vasodilator responses of the UA 
and other systemic vessels during pregnancy.21-23 Given 
that pregnancy increases AT2-dependent vasodilatation in 
isolated rat aortae,24 and treatment with an AT2 blocker 
abolishes the normal mid-pregnancy-associated fall in sys-
temic blood pressure in mice25 and this fall in blood pres-
sure is absent in mice lacking the expression of the Ang-II 
AT2 receptor,26 we considered that AT2-mediated vasodila-
tation might also be an important contributor to the 
pregnancy-associated increase in vasodilator response.
Recently the mouse has emerged as an important model 
for studying maternal physiological responses to pregnancy, 
since the availability of genetically modified strains pro-
vides unique opportunities for identifying the genes and 
their mode of action on relevant cardiovascular systems.27 
Similar to humans, pregnancy in the mouse decreases vascu-
lar resistance, raises CO, lowers blood pressure as well as 
the pressor response to Ang-II,28,29 and directs much of the 
increase in flow to the uteroplacental circulation.5 To estab-
lish the role of Ang-II receptors in modulating vascular 
changes during pregnancy and, specifically, the role of the 
AT2 receptor in opposing AT1-mediated vasoconstric-
tion,25,30-32 we studied the blood pressure response to preg-
nancy and the effects of Ang-II as well as other agonists on 
UA vasoreactivity in the mouse. We hypothesised that 
enhanced AT2-mediated signalling augmented UA vasodila-
tation, with such augmentation being particularly evident at 
mid-pregnancy or the time of greatest fall in systemic blood 
pressure. To test this hypothesis we measured blood pressure 
before and then throughout gestation in C57BL/6J mice and 
used wire myography to compare the contractile and relaxa-
tion responses of isolated uterine vessels in non-pregnant, 
mid (day 12–13) and late (day 18–19) pregnant animals.
Materials and methods
Animals
All procedures were approved by the Wake Forest 
University School of Medicine Institutional Animal Care 
and Use Committee. Female and male C57BL/6J mice were 
obtained from Charles River Laboratories Inc, Wilmington, 
MA, USA. Mice were housed in polypropylene cages in a 
temperature and humidity-controlled environment. Animal 
housing facilities were controlled on a 12-h light, 12-h dark 
cycle and mice were given free access to standard labora-
tory chow and water. Non-pregnant (NP) female mice were 
used between 8 and 12 weeks of age. Mature cycling female 
mice (7–8 weeks old) were used for breeding purposes and 
studied 2–3 weeks later; the presence of a vaginal plug was 
taken as indication of day 0 of pregnancy.
Blood pressure and heart rate measurements
All mice were trained to become familiar with the compu-
terised programmed tail-cuff blood pressure analysis sys-
tem (Visitech Systems Inc, Apex, NC, USA) before the data 
were collected, as previously described.25 All data were col-
lected between 8:00 and 10:00 AM. This system permits 
measuring systolic blood pressure (SBP) and heart rate 
(HR) in each animal from, on average, 30 values. In NP 
animals SBP and HR were recorded during four consecutive 
days. After breeding, SBP and HR were recorded daily 
throughout pregnancy. SBP and HR for middle gestation 
(MG) were determined as the average of those measure-
ments obtained at day 12 and 13 of pregnancy, while the 
values for the late gestation (LG) group were determined as 
the average of the day 18 and 19 values.
Arterial segment preparation
Female NP mice, at MG or LG were killed by cervical 
dislocation, the uterine horn was removed by laparotomy 
and the tissue placed directly into ice-cold Krebs buffer. 
Under a dissecting microscope the main UA was identified 
and dissected free from fat and connective tissue. Uterine 
vessels from NP (90 µm), MG (120 µm) and LG (150 µm) 
animals were cut into 1.5–2 mm segments and mounted 
between an isometric force transducer (Kistler Morce DSC 
6, Seattle, WA, USA) and a displacement device on a myo-
graph (Multi Myograph, Model 610M Danish Myo 
Technologies, Aarhus, Denmark) using two stainless steel 
wires (diameter 25 µm). The myograph organ bath (5 ml) 
was filled with Krebs buffer maintained at 37°C and aer-
ated with 95% O2–5% CO2. The vessels were washed and 
incubated for 30 min before the normalisation procedure 
was performed as described.33 Each arterial segment was 
stretched in a stepwise manner and the internal circumfer-
ence and corresponding wall tension at each stretch were 
calculated and plotted to produce a resting wall tension–
internal circumference curve for that particular artery 
using the Myodaq software (National Instruments 
Corporation, Denmark). Uterine segments were normal-
ised to 0.9 of L13.3 kPa as described.33 After obtaining the 
optimal diameter, a 30-min equilibration period preceded 
the addition of test substances.
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Response to depolarising concentrations of KCl
In order to test the viability of the arterial preparations and 
determine responses to non-receptor-mediated contraction, 
segments of UA were exposed successively to increasing 
concentrations of potassium chloride (KCl). Arterial seg-
ments were exposed to eight different concentrations of 
KCl (6.25–62.5 mM), with each dose maintained for 2 min 
and the segment washed with Krebs buffer before the sub-
sequent concentration was introduced.
Response to U46619
To test the response to a receptor-mediated contraction, 
arterial segments were exposed to a cumulative concentra-
tion-response curve of the thromboxane analogue U41669 
by exposing arteries to eight (10–9–10–6.75 M) increasing 
concentrations, with each subsequent dose being intro-
duced after a steady response had been reached.
Response to angiotensin II
In order to avoid tachyphylaxis and desensitisation, Ang-II 
was used only once in each arterial segment. Ang-II was 
administered 30 min after the last contraction of the KCl 
curve had been relaxed with Krebs buffer, the segments 
washed three times, and Ang-II response was tested as the 
maximal response to a single 10-7 M dose. Since the shape 
of the Ang-II contraction is such that there is an initial spike 
and then decline (as shown in figure 5A), we elected to 
measure the contraction at the spike as this represented the 
point of maximal force generation. In parallel experiments, 
different arterial segments were preincubated for 15 min 
with the AT1 receptor inhibitor losartan at 10-5 M or the AT2 
receptor inhibitor PD123319 at 10-5 M. The Ang-II receptor 
antagonists produced different effects on Ang-II contrac-
tion; losartan 10-5 M blocked most of the response, whereas 
PD123319 at the same dose of 10-5 M increased the response 
in the MG group.
Response to acetylcholine
A cumulative concentration-response curve for acetylcho-
line (ACh) was constructed by adding 13 different concen-
trations (ACh 10–10–10–4 M) to vessels pre-constricted with 
3 × 10-8 M U46619 or 80% of the maximal constriction, 
with each subsequent dose being introduced at 2-min inter-
vals. In parallel experiments, different arterial segments 
were preincubated for 15 min with the nitric oxide synthase 
inhibitor L-NAME at a concentration of 10-4 M.
Solutions and drugs
Krebs buffer contained (in mM) NaCl 118.5, NaHCO3 25, 
KCl 4.7, KH2PO4 1.2, MgSO4 1.2, CaCl2 2.5, and glucose 
5.5 with a final pH of 7.4. In solutions used for testing KCl 
depolarising effects, NaCl was replaced by an equimolar 
amount of KCl. All drugs and agonists used were obtained 
from Sigma Chemical Co. (St. Louis, MO, USA).
Data analysis
Myodata 2.02 (National Instruments Corporation, 
Denmark), Excel, and GraphPad Prism version 5.0 
(GraphPad Software, San Diego, CA, USA) were used to 
analyse the data. Concentration-response curves for KCl, 
ACh and U46619 were analysed by fitting individual 
experimental data to a logistic curve to determine maximal 
response and sensitivity. The curve was of the form Y = 
bottom + (top - bottom) / (1 +10(LogEC50 - X)* Hill Slope)) where 
X is the logarithm of the concentration and Y is the response; 
the EC50 values reported are derived from these fits. The 
contractile response to KCl was expressed in mN/mm2 as 
units of arterial wall tension (AWT) (AWT = force / 2 × 
length of vessel). For each arterial segment the maximal 
response to KCl was calculated, and the response to con-
tractile agonists was expressed as percent of the corre-
sponding maximal response to KCl. Relaxant responses 
were expressed as the percent of reduction of U46619-
induced contraction. Sensitivity was expressed as pD2 (pD2 
= -log [EC50]) with EC50 being the concentration of agonist 
producing 50% of the maximal response. Data are expressed 
as mean ± SE. One-way analysis of variance (ANOVA) 
with Bonferroni’s multiple comparisons was used to deter-
mine significant differences. A p < 0.05 was accepted as an 
indication of statistical significance.
Results
Blood pressure and heart rate measurements
A reduction in SBP (figure 1A) is evident at mid-gestation, 
starting approximately at day 10 and reaching its peak at 
day 12 with a 10% maximal reduction in SBP compared 
with pre-pregnant values. In late gestation (days 18 and 19) 
SBP recovered to pre-pregnancy values. A similar pattern 
was observed for the recordings of HR, with approximately 
12% reduction in mid-gestation and recovery in late gesta-
tion (figure 1B). The averages of values at mid-gestation 
(days 12 and 13) showed a statistically significant reduction 
in SBP (figure 1C) and HR (figure 1D) compared with pre-
pregnancy values, whereas there were no such differences 
in late gestation.
In vitro experiments
As shown in table 1, isolated UA segments showed increas-
ing external diameters from NP to MG and LG groups. The 
optimal diameters showed an increase of 23% and 73% in 
mid and late gestation compared with arteries from NP 
animals.
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Response to KCl and U46619. Greater maximal contraction 
(Kmax) values were observed in MG or LG compared with 
NP animals (table 1 and figure 2A and 4, 204% and 310% 
in Kmax respectively). No significant differences were 
observed in the sensitivity to KCl. The absolute values for 
the contractile response to U46619 followed a similar pat-
tern, with maximal tension values increasing progressively 
with gestation (0.79 ± 0.09, 2.27 ± 0.11 and 2.54 ± 0.36 mN/
mm2 in NP, MG and LG animals, respectively, figure 3. 
Expressed as % of Kmax, the maximal response to U46619 
was significantly lower in LG compared with the NP group. 
There were no changes in sensitivity at any time point 
(table 1 and figure 2B).
Response to acetylcholine. In arteries pre-constricted with a 
sub maximal dose of U46619 (3 × 10-8 M) to achieve 80% 
of the maximal contraction, maximal relaxation to acetyl-
choline (AChMAX) was greater in MG and LG compared 
with the NP state (figure 4A and table 2). Sensitivity to 
acetylcholine, expressed as pD2, increased as gestation 
progressed (table 2). Treatment with L-NAME diminished 
AChMAX in all the groups studied and decreased sensitivity 
in the MG and LG groups (figure 4B and table 2).
Response to Ang-II. As shown in figure 5A, 10-7 M Ang-II 
elicits a transient response. As was the case for KCl and 
U46619, absolute contractile response to Ang-II was 
increased during pregnancy with values of 0.5 ± 0.1, 1.7 ± 
0.3 and 2.6 ± 0.5 mN/mm2 in NP, MG and LG animals, 
respectively (figure 3). Pre-incubation with the AT2 recep-
tor blocker PD123319 (10-5 M) induced a greater contrac-
tion in the MG group compared with the controls (figure 
5B). No effects of AT2 receptor blockade were observed in 
Table 1. Diameters and contractile responses to potassium 
chloride (KCl) and U46619 in isolated segments of mice uterine 
artery (UA)
Non-pregnant 
(NP)
Mid-gestation 
(MG)
Late gestation 
(LG)
Animals/Arteries 5/20 8/30 7/28
Optimal diameter 
(OD), µm
166 ± 5 205 ± 16* 287 ± 9*†
KMAX, N/m 0.67 ± 0.09 2.04 ± 0.07* 2.75 ± 0.36*†
KCl, pD2 1.73 ± 0.03 1.78 ± 0.04 1.76 ± 0.04
U46619MAX, 
%Kmax
114 ± 4 110 ± 5 101 ± 3*
U46619, pD2 7.92 ± 0.05 7.89 ± 0.08 7.79 ± 0.08
Optimal diameter refers to diameters of UA segments measured 
after the normalisation procedure. Contractile responses for KCl are 
expressed as absolutes values of tension in N/m, responses for U46619 
are expressed as % of maximal KCl response (KMAX); sensitivity is 
expressed as pD2. Data are shown as mean ± SEM. 
*p < 0.05 vs. non-pregnant; †p < 0.05 vs. mid gestation by ANOVA.
Table 2. Parameters of the ACh response in isolated segments of mice uterine artery (UA)
Non-pregnant (NP) Mid-gestation (MG) Late gestation (LG)
Control + L-NAME Control + L-NAME Control + L-NAME
AChMAX, % 79 ± 6 18 ± 2‡ 91 ± 3* 72 ± 6‡ 94 ± 4* 84 ± 2‡
ACh pD2 6.62 ± 0.34 6.49 ± 0.23 7.62 ± 0.09* 6.98 ± 0.18‡ 7.9 ± 0.06*† 7.45 ± 0.22‡
Maximal relaxation (AChMAX) and sensitivity (ACh pD2) to acetylcholine in the UA of non-pregnant, mid gestation and late gestation pregnant mice. 
Values for control arteries and arteries treated with the nitric oxide synthase inhibitor (+L-NAME 10-4 M) are shown. 
* p < 0.05 vs. non-pregnant; † p < 0.05 vs. mid gestation; ‡ p < 0.05 vs. control by ANOVA.
Figure 1. Systolic blood pressure (SBP; A) and heart rate (HR; 
B) in non-pregnant (NP, n = 6), mid gestation (MG, n = 11) and 
late gestation (LG, n = 7) pregnant mice. Dotted vertical line 
indicates day of breeding. C and D: Data correspond to the 
average of 4 days for NP (white box), days 12 and 13 for MG 
(black box) and days 18 and 19 for LG (grey box). Data are 
shown as mean ± SEM. *p < 0.05 vs. NP and LG, † p < 0.05 vs. 
LG by ANOVA.
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NP or LG groups. Pre-incubation of the arterial segments 
with losartan 10-5 M, to inhibit AT1 receptor-mediated 
responses, abolished the Ang-II response in all three groups.
Discussion
In this study we measured BP and HR during gestation in 
wild-type C57BL/6J mice and vascular reactivity in iso-
lated UA. Our findings of a lower BP at mid-pregnancy 
agreed with previous reports,25,34 while HR responses seem 
more variable.28,29,34,35 Given the importance of Ang-II 
responses in the uteroplacental circulation during preg-
nancy and the differing contributions of the AT1 and AT2 
receptors in mediating this response, we studied the role of 
the AT2 receptor in modulating UA Ang-II contractile 
response. Our results showed that pregnancy increased the 
contractile response to Ang-II in the mouse UA, and that 
this contraction was further increased in the presence of the 
AT2 inhibitor PD123319 at mid-gestation. We interpreted 
Figure 2. Potassium chloride (KCl)-induced (A) and U46619-
induced (B) vasoconstriction in uterine arteries from  
non-pregnant (NP, n = 5), mid gestation (MG, n = 8) and 
late gestation (LG, n = 7) mice. Responses are expressed as 
absolutes values of tension (AWT; arterial wall tension) in N/m 
(A) or as % of maximal KCl response (%KMAX, B). Data are 
shown as mean ± SEM. *p < 0.05 vs. NP, † p < 0.05 vs. MG, in 
maximal response by ANOVA.
Figure 4. Maximal contractile responses of isolated uterine 
artery during mouse pregnancy. Absolute maximal responses to 
KCl, U46619 and Ang-II expressed as mN/mm2 in non-pregnant 
(NP, n = 5), mid gestation (MG, n = 8) and late gestation (LG,  
n = 7). Data are shown as mean ± SEM.  # p < 0.05 vs. NP 
values, * p < 0.05 vs. MG, † p < 0.05 vs. KCl.
Figure 3. Acetylcholine-induced relaxation in non-pregnant 
(NP), mid gestation (MG) and late gestation (LG) uterine 
arteries pre-constricted with 3 × 10-8 M U46619. Responses are 
expressed as percentage of the contraction response.  
A; response in control arteries. B; response in arteries  
pre-treated with 10-4 M L-NAME. Data are shown as  
mean ± SEM. * p < 0.05 vs. NP by ANOVA.
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these results as supporting the likelihood that increased 
AT2-mediated activity opposed the contractile effects of 
Ang-II and contributed to enhanced UA vasodilatation. The 
time at which the greater inhibitory effect of PD123319 
was observed coincided with that at which systemic blood 
pressure was lowest, suggesting that AT2 receptor- 
mediated signalling might play a more general role in 
pregnancy-associated vasodilatation.
The UA undergoes significant structural and functional 
changes during pregnancy.6 In particular, the UA doubles in 
diameter in humans and other species,2 and increased 
responses to KCl have been observed in sheep arteries.8 
Similarly, we observed increased diameters and greater 
responses to KCl in UA from pregnant versus non-pregnant 
mice. Our values for maximal response to KCl at late gesta-
tion (2.75 ± 0.36 mN/mm2) agree with those reported for the 
mice UA at equivalent gestational age (~2.5 mN/mm2).21 
Increased KCl-mediated contraction during pregnancy sug-
gests the presence of more vascular smooth muscle cells, 
which in turn is likely to be due to the pregnancy-associated 
increase in sensitivity of UA smooth muscle cells to prolif-
erative stimuli.7 Unique to pregnancy is that these changes 
lead to outward hypertrophic remodelling with increased 
cross-sectional area.6,36 Given these changes in smooth 
muscle content, we expressed the tension developed as % 
of the maximal response to KCl in order to allow the evalu-
ation of agonist responses independent of the amount of 
smooth muscle per unit of surface area. Therefore we inter-
pret the lower contractile response to U46619 in LG arteries 
as indicating an attenuation of UA constrictor responses; 
this is similar to previous observations in rats,24 guinea 
pigs37 and mice.29
The incomplete inhibition of the vasodilator response to 
acetylcholine observed in the present study following 
L-NAME treatment in pregnant UA suggests that mecha-
nisms other than NO influence UA vasodilatation during 
murine pregnancy. The importance of NO production during 
pregnancy has been widely recognised. However, since 
knockout mice for any of the NO synthase isoforms do not 
develop hypertension,38 it appears likely that mechanisms 
other than NO are also involved. Such additional vasodila-
tors are likely to be cyclo-oxygenase products, specifically 
PGI2,22,39 as well as endothelium-derived hyperpolarising 
factor (EDHF).40,41 A new observation from the present study 
is that AT2-mediated vasodilatation may also be involved.
The UA exhibited a different response to U46619 and 
Ang-II in during pregnancy; whereas the U46619 maximal 
contraction was lower in LG, we interpret the lower Ang-II 
in MG as an indication of an Ang-II-specific mechanism 
activated earlier in gestation. The vasoconstrictor actions of 
the Ang-II system have been well studied during pregnancy, 
but comparatively less attention has been devoted to its 
AT2-mediated vasodilatory effects. During human preg-
nancy the systemic and uterine circulations become less 
responsive to the contractile effects of Ang-II despite the 
increases occurring in several components of the RAS. 
While many factors influence the RAS, our results, show-
ing an increased inhibitory effect of PD123319 on Ang-II 
stimulation at mid-gestation, suggest a role for increased 
AT2-mediated signalling that acts to oppose AT1-mediated 
UA vasoconstriction at mid-pregnancy. Consistent with the 
results reported here are studies showing that PD123319 
blocks the mid-gestation decrease in BP in mice, and that 
AT2-receptor-deficient strains lack this normal mid- 
pregnancy BP fall.25,26 The availability of AT1 and AT2 
receptor knockout mice creates the possibility of further 
evaluating the role of AT2-mediated signalling in lowering 
peripheral vascular resistance during pregnancy. Studies of 
uterine blood flow and vascular reactivity in these knockout 
strains are needed to establish the mechanisms whereby the 
AT2-receptor-mediated vasodilatation influences UA and 
systemic vascular control during pregnancy. Information as 
to whether AT2 receptor signalling is disrupted in preec-
lampsia would enlarge our understanding of this still poorly 
understood disease, known to be a major cause of maternal 
and infant morbidity and mortality. A role for AT2-mediated 
signalling in decreasing BP and raising UA blood flow 
Figure 5. Contractile response to Ang-II in mouse uterine 
artery (UA). A. Representative trace showing the response 
to Ang-II in UA of a control pregnant mouse at mid gestation 
compared with the response to 62.5 mM KCl (w = wash).  
B. Absolute maximal response to Ang-II expressed as mN/mm2 
in control arteries, arteries pre-treated with PD123319 10-5 M 
and arteries pre-treated with losartan 10-5 M as indicated, in 
non-pregnant (NP) (n = 5), mid gestation (MG) (n = 8) and late 
gestation (LG) (n = 7) groups. Data are shown as mean ± SEM. 
* p < 0.05 vs. MG control, † p < 0.05 vs. control and PD123319 
treated arteries by ANOVA.
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might also be a potentially important target for treating the 
uteroplacental ischaemia characteristic of this disorder.42,43
Funding
This research was supported by the National Institute of Health 
(Grants HD-17644 to JCR; and HL-079647 to LGM).
Conflict of interest
The authors declare that they have no conflicts of interest.
References
 1.  Curran-Everett D, Morris KG, Jr. and Moore LG. Regional 
circulatory contributions to increased systemic vascular con-
ductance of pregnancy. Am J Physiol Heart Circ Physiol 
1991; 261: H1842–H1847.
 2.  Palmer SK, Zamudio S, Coffin C, Parker S, Stamm E and 
Moore LG. Quantitative estimation of human uterine artery 
blood flow and pelvic blood flow redistribution in pregnancy. 
Obstet Gynecol 1992; 80: 1000–1006.
 3.  Thaler I, Manor D, Itskovitz J, et al. Changes in uterine blood 
flow during human pregnancy. Am J Obstet Gynecol 1990; 
162: 121–125.
 4.  Rosenfeld CR. Distribution of cardiac output in ovine preg-
nancy. Am J Physiol Heart Circ Physiol 1977; 232: H231–
H235.
 5.  Mu J and Adamson SL. Developmental changes in hemody-
namics of uterine artery, utero- and umbilicoplacental, and 
vitelline circulations in mouse throughout gestation. Am J 
Physiol Heart Circ Physiol 2006; 291: H1421–H1428.
 6.  Osol G and Mandala M. Maternal uterine vascular remod-
eling during pregnancy. Physiology 2009; 24: 58–71.
 7.  Keyes LE, Moore LG, Walchack SJ and Dempsey EC. 
Pregnancy-stimulated growth of vascular smooth muscle 
cells: importance of protein kinase C-dependent synergy 
between estrogen and platelet-derived growth factor. J Cell 
Physiol 1996; 166: 22–32.
 8.  Annibale DJ, Rosenfeld CR and Kamm KE. Alterations in 
vascular smooth muscle contractility during ovine preg-
nancy. Am J Physiol Heart Circ Physiol 1989; 256: H1282–
H1288.
 9.  de Gasparo M, Catt KJ, Inagami T, Wright JW and Unger 
T. International Union of Pharmacology. XXIII. The angi-
otensin II receptors. Pharmacol Rev 2000; 52: 415–472.
10.  Mehta PK and Griendling KK. Angiotensin II cell signaling: 
physiological and pathological effects in the cardiovascular 
system. Am J Physiol Cell Physiol 2007; 292: C82–C97.
11.  Carey RM, Lin XH and Siragy HM. Role of the angiotensin 
AT(2) receptor in blood pressure regulation and therapeutic 
implications. Am J Hypertens 2001; 14: 98S–102S.
12.  Carey RM. Cardiovascular and renal regulation by the angi-
otensin type 2 receptor: the AT2 receptor comes of age. 
Hypertension 2005; 45: 840–844.
13.  Carey RM and Padia SH. Angiotensin AT2 receptors: con-
trol of renal sodium excretion and blood pressure. Trends 
Endocrinol Metab 2008; 19: 84–87.
14.  Baker PN, Broughton Pipkin F and Symonds EM. Platelet 
angiotensin II binding and plasma renin concentration, 
plasma renin substrate and plasma angiotensin II in human 
pregnancy. Clin Sci (Lond) 1990; 79: 403–408.
15.  Gant NF, Daley GL, Chand S, Whalley PJ and MacDonald 
PC. A study of angiotensin II pressor response throughout 
primigravid pregnancy. J Clin Invest 1973; 52: 2682–2689.
16.  Gant NF, Worley LJ, Everett RB and MacDonald PC. Control 
of vascular responsiveness during human pregnancy. Kidney 
Int 1980; 18: 253–258.
17.  Burrell JH and Lumbers ER. Angiotensin receptor sub-
types in the uterine artery during ovine pregnancy. Eur 
J Pharmacol 1997; 330: 257–267.
18.  Cox BE, Rosenfeld CR, Kalinyak JE, Magness RR and Shaul 
PW. Tissue specific expression of vascular smooth muscle 
angiotensin II receptor subtypes during ovine pregnancy. Am 
J Physiol Heart Circ Physiol 1996; 271: H212–H221.
19.  Cox BE, Word RA and Rosenfeld CR. Angiotensin II recep-
tor characteristics and subtype expression in uterine arteries 
and myometrium during pregnancy. J Clin Endocrinol Metab 
1996; 81: 49–58.
20.  Abadir PM, Carey RM and Siragy HM. Angiotensin AT(2) 
receptors directly stimulate renal nitric oxide in bradykinin 
B-2-receptor-null mice. Hypertension 2003; 42: 600–604.
21.  Kusinski LC, Baker PN, Sibley CP and Wareing M. In vitro 
assessment of mouse uterine and fetoplacental vascular func-
tion. Reprod Sci 2009; 16: 740–748.
22.  Bird IM, Zhang L and Magness RR. Possible mechanisms 
underlying pregnancy-induced changes in uterine artery 
endothelial function. Am J Physiol Regul Integr Comp 
Physiol 2003; 284: R245–R258.
23.  Sladek SM, Magness RR and Conrad KP. Nitric oxide and 
pregnancy. Am J Physiol Regul Integr Comp Physiol 1997; 
272: R441–R463.
24.  Stennett AK, Qiao X, Falone AE, Koledova VV and Khalil 
RA. Increased vascular angiotensin type 2 receptor expres-
sion and NOS-mediated mechanisms of vascular relaxation 
in pregnant rats. Am J Physiol Heart Circ Physiol 2009; 296: 
H745–H755.
25.  Kai C, Merrill DC and Rose JC. The importance of angi-
otensin II subtype receptors for blood pressure control during 
mouse pregnancy. Reprod Sci 2007; 14: 694–704.
26.  Carey LC and Rose JC. The midgestational maternal blood 
pressure decline is absent in mice lacking expression of the 
angiotensin II AT2 receptor. J Renin Angiotensin Aldosterone 
Syst 2010; In Press.
27.  Rossant J and Cross JC. Placental development: Lessons 
from mouse mutants. Nat Rev Genet 2001; 2: 538–548.
28.  Kulandavelu S, Qu D and Adamson SL. Cardiovascular func-
tion in mice during normal pregnancy and in the absence of 
endothelial NO synthase. Hypertension 2006; 47: 1175–1182.
29.  Wong AYH, Kulandavelu S, Whiteley KJ, Qu D, Langille BL 
and Adamson SL. Maternal cardiovascular changes during 
pregnancy and postpartum in mice. Am J Physiol Heart Circ 
Physiol 2002; 282: H918–H925.
Pulgar et al. 183
30.  Takeda-Matsubara Y, Iwai M, Cui TX, et al. Roles of angi-
otensin type 1 and 2 receptors in pregnancy-associated blood 
pressure change. Am J Hypertens 2004; 17: 684–689.
31.  Saito T, Ishida J, Takimoto-Ohnishi E, et al. An essential role 
for angiotensin II Type 1a receptor in pregnancy-associated 
hypertension with intrauterine growth retardation. FASEB J 
2004; 18: 388–390.
32.  Jones ES, Vinh A, McCarthy CA, Gaspari TA and Widdop 
RE. AT2 receptors: Functional relevance in cardiovascular 
disease. Pharmacol Ther 2008; 120: 292–316.
33.  Mulvany MJ and Aalkjaer C. Structure and function of small 
arteries. Physiol Rev 1990; 70: 921–961.
34.  Butz GM and Davisson RL. Long-term telemetric measure-
ment of cardiovascular parameters in awake mice: a physi-
ological genomics tool. Physiol Genomics 2001; 5: 89–97.
35.  Eghbali M, Deva R, Alioua A, et al. Molecular and functional 
signature of heart hypertrophy during pregnancy. Circ Res 
2005; 96: 1208–1216.
36.  van der Heijden OWH, Essers YPG, Fazzi G, Peeters LLH, 
De Mey JGR and van Eys GJJM. Uterine artery remodeling 
and reproductive performance are impaired in endothelial 
nitric oxide synthase-deficient mice. Biol Reprod 2005; 72: 
1161–1168.
37.  White MM, McCullough RE, Dyckes R, Robertson AD and 
Moore LG. Effects of pregnancy and chronic hypoxia on 
contractile responsiveness to alpha 1-adrenergic stimulation. 
J Appl Physiol 1998; 85: 2322–2329.
38.  Shesely EG, Gilbert C, Granderson G, Carretero CD, 
Carretero OA and Beierwaltes WH. Nitric oxide synthase 
gene knockout mice do not become hypertensive during 
pregnancy. Am J Obstet Gynecol 2001; 185: 1198–1203.
39.  Valdes G, Kaufmann P, Corthorn J, Erices R, Brosnihan B and 
Joyner-Grantham J. Vasodilator factors in the systemic and local 
adaptations to pregnancy. Reprod Biol Endocrinol 2009; 7: 79.
40.  Fulep EE, Vedernikov YP, Saade GR and Garfield RE. The 
role of endothelium-derived hyperpolarizing factor in the 
regulation of the uterine circulation in pregnant rats. Am J 
Obstet Gynecol 2001; 185: 638–642.
41.  Keyes L, Rodman DM, Curran-Everett D, Morris K and 
Moore LG. Effect of K+ATP channel inhibition on total and 
regional vascular resistance in guinea pig pregnancy. Am J 
Physiol Heart Circ Physiol 1998; 275: H680–H688.
42.  Myatt L and Webster LP. Vascular biology of preeclampsia. 
J Thromb Haemost 2009; 7: 375–384.
43.  Sibai BM and Frangieh A. Maternal adaptation to pregnancy. 
Curr Opin Obstet Gynecol 1995; 7: 420–426.
